Abbott Aveir VR

Main Article: Pacemakers (Global Market)

History

2023: Start of Sales

On May 20, 2023, Abbott announced the start of sales of the world's first dual-chamber electrodeless pacemaker, the Aveir DR device, created for patients with slowed heart rate.

Unlike traditional pacemakers, electrodeless devices are injected directly into the heart using a minimally invasive procedure using a catheter. This eliminates the need for electrodes and a pulse generator. Aveir DR delivers electrical signals directly to the heart muscle, restoring normal heart rhythm.

Abbott Aveir DR

Abbott notes that many people require electrocardiostimulation of both the right atrium and right ventricle. But electrodeless products available on the commercial market are single-chamber ventricular devices. This is explained by the complexity of wireless synchronization of two system components. The Aveir DR pacemaker allows you to bypass this limitation.

Abbott has developed the first implant-implant technology of its kind (i2i). It provides stable communication and synchronization between two wireless pacemakers. These devices are able to detect changes in the heart rate and, if necessary, stimulate the corresponding chamber of the heart. A special scheme for installing implants makes it possible to easily remove them through minimal surgery.

The Aveir DR installation success rate reaches 98.3%. A comprehensive study suggests that a two-chamber electrodeless pacemaker functions properly in the daily life of patients. The absence of complications associated with the installation of devices is also shown. The solution is expected to help a large number of people around the world who have a slowed heart rate.^[1]

2022: Device Announcement

In early April 2022 Abbott , he released the first electrodeless pacemaker Aveir VR in his range. The device is designed to accelerate a slow heart rate, and according to information the company, Aveir VR has a longer battery life, a pre-mapping system and the ability to easily remove if necessary.

Before implanting the device, Abbott's system assesses electrical signals hearts to determine the perfect location of the device, something no other pacemaker offers, the company claims. The Aveir device is then VR placed in the right ventricle hearts in a minimally invasive procedure that uses only a catheter conducted through blood vessels.

Abbott launches first electrodeless pacemaker

It is also the first lead-free pacemaker designed so that it can be easily removed when changing the therapeutic needs of the patient or if the device needs to be replaced. The extraction operation can be done by the same minimally invasive method used to install it.

The device's system delivers electrical pulses as heart rate deceleration is detected compared to the norm, rather than sending a steady stream of pulses. According to the developers of the device, with standard programming, the pacemaker battery can last twice as long as other lead-free pacemakers on the market for April 2022.

{{quote 'Aveir VR wireless pacemaker was designed to make implantation and retrieval processes as easy as possible for doctors and improve existing capabilities! Our goal is to continue developing the success of the device in order to offer even more first-of-its-kind products that revolutionize the treatment of abnormal heart rhythms in the future, "said Randel Woodgrift, senior vice president of heart rhythm management at Abbott. }} According to the results of the study, which was presented in 2021, Aveir VR was successfully implanted in 98% of patients, and about 96% of them reached the therapeutic threshold of electrocardiostimulation, sounding amplitude and safety endpoints six weeks after the procedure. In addition, pre-mapping technology helped doctors implant devices in the right place on the first or second attempt 96% of the time.^[2]

Notes